The Clinical Significance of Anti-cyclic Citrullinated Peptide Antibodies in Juvenile Rheumatoid Arthritis.
10.4078/jrd.2014.21.5.236
- Author:
Min KANG
1
;
Tae Young SOHN
;
Sung Hye KIM
;
Hae Ran LEE
;
Hee Jung KANG
;
Kwang Nam KIM
Author Information
1. Department of Pediatric and Adolescent Medicine, College of Hallym University Sacred Heart Hospital, Anyang, Korea. kwangnamkim@naver.com
- Publication Type:Original Article
- Keywords:
Juvenile rheumatoid arthritis;
Polyarticular;
Cyclic citrullinated peptide
- MeSH:
Antibodies*;
Arthralgia;
Arthritis;
Arthritis, Juvenile*;
Enzyme-Linked Immunosorbent Assay;
Humans;
Medical Records;
Retrospective Studies
- From:Journal of Rheumatic Diseases
2014;21(5):236-240
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aim of this study was to determine the clinical significance of anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile rheumatoid arthritis (JRA). METHODS: Sera for anti-CCP assay were obtained from 142 patients with arthralgia in our hospital during the period between November 2010 and October 2011. On the basis of medical records, 83 patients with JRA were designated to the study group, and 59 patients with arthralgia but were treated as transient arthritis to the control group. The values of anti-CCP were then analyzed retrospectively. We used the enzyme linked immunosorbent assay (ELISA) for detecting anti-CCP. RESULTS: Positive anti-CCP values were found in the sera of 11 patients with JRA (13.3%), one patient presented with pauciarticular JRA and the others with polyarticular JRA. There was a statistically significant difference in the anti-CCP values between the JRA group and the control group. However, patients with systemic JRA and arthralgia without JRA had no anti-CCP. Especially, 10 out of 14 (71.4%) patients with RF-positive polyarticular JRA had anti-CCP. In addition, the rate of positive anti-CCP was significantly higher in patients with polyarticular JRA than in the control group. CONCLUSION: We expect that the presence of anti-CCP may help to evaluate the severity of diseases in patients with JRA. Anti-CCP can be an important biomarker for making early intensive therapeutic decision in patients with polyarticular JRA, which might have more severe course and longer disease duration.
